(Q44247530)

1 December 2017

title

Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban (English)

1 reference

1 December 2017

1 reference

David J Schneider

1

1 reference

1 December 2017

Howard C Herrmann

2

1 reference

1 December 2017

Nasser Lakkis

3

1 reference

1 December 2017

Frank Aguirre

4

1 reference

1 December 2017

Ying Wan

5

1 reference

1 December 2017

Atul Aggarwal

6

1 reference

1 December 2017

Samer S Kabbani

7

1 reference

1 December 2017

Peter M DiBattiste

8

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

American Journal of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

90

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

1421-1423

1 reference

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Differential effects of anticoagulants on the activation of platelets ex vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902892-8

10.1016/S0002-9149(02)02892-8

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference